$TMO

CASPER MARC N sold $2.9M of TMO (indirect holdings)

CASPER MARC N (Chairman & CEO) sold 5,000 indirectly-held shares of THERMO FISHER SCIENTIFIC INC. (TMO) at an average of $575.23 ($566.26–$577.56, $2.88M total) across 11 trades on 2026-08-05 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · CASPER MARC N
Published Aug 7, 2026, 9:26 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 7, 2026, 9:30 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$TMO
Neutral
medium confidence
Mentioned
$TMO
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TMONeutralLow
01

Why it matters

The newest fact is the disclosed sale size ($2.876M) and execution window ($566.26 to $577.56) under a pre-arranged plan, which can slightly influence short-term sentiment but is not a fundamental update.

02

Market read

Traders may monitor for follow-on insider activity, but this specific disclosure is unlikely to drive a durable repricing without additional catalysts.

03

What to watch

The transaction is indirect and spread across 11 trades, which further reduces interpretability versus a single large, discretionary sale.

Relevance 5/10Novelty 3/10Timing: filed 2026-08-07, sale executed 2026-08-05

Background

The article is an SEC Form 4 insider transaction disclosure for Thermo Fisher Scientific, reported from an officer/director role with an indicated 10b5-1 plan.

Company-level read

Ticker impact

$TMONeutralMedium confidence
Context

Thermo Fisher CEO Casper Marc N sold $2.88M of TMO shares via a 10b5-1 plan on 2026-08-05 at $566.26 to $577.56.

Expected impact

Likely limited near-term impact; any reaction should be small and fade unless accompanied by other company-specific news.

Evidence & confidence

The filing is a Form 4 insider transaction with stated 10b5-1 pre-arrangement, which typically reduces the informational content versus discretionary selling.

Market effects

Minimal; insider selling at a single large healthcare/life-sciences tools name does not materially change sector fundamentals.

None indicated.

None indicated.

Counterpoint

A 10b5-1 sale can coincide with planned liquidity needs and does not necessarily reflect bearish views; traders may overreact to the headline.

Key entities

  • THERMO FISHER SCIENTIFIC INC.

    Subject of the Form 4 insider sale disclosure.

  • CASPER MARC N

    Chairman & CEO who executed an open-market sale under a 10b5-1 plan.

Related articles

$TMOMedAI 8/10

Thermo Fisher (TMO) Climbs 8.7% on Solid Earnings, Price Target Upgrades

Thermo Fisher Scientific (TMO) shares rose 8.71% to close at $572.32 after Q2 results. Net income increased 7% to $1.736B and revenue rose 10% to $11.99B, according to the company. Jefferies, Leerink Partners, and Evercore ISI raised price targets to $630, $620, and $615. The board authorized a $0.47 dividend per share.

$TMOMed

Thermo Fisher TMO Stock Draws Bullish Calls Ahead Of Q2

Thermo Fisher Scientific (TMO) shares rose about 9% after upbeat earnings and guidance, with the stock moving roughly from $501 to $574. Deutsche Bank reiterated a Buy and set a $630 target; Baird raised its target to $652. The company also announced an Arcturus collaboration on ARCT-032 and reaffirmed a $0.47 quarterly dividend.